Absci targets large pharmaceutical companies developing biologics and therapeutic proteins, as well as emerging and established biotechnology companies seeking advanced protein engineering solutions. The company's technology-forward strategy creates a scalable model applicable in human therapeutics and expanding into adjacent markets such as veterinary medicine.
Cyborg Score Rationale
Absci specializes in using generative AI combined with wet lab technologies to design and validate novel biologic therapeutics, representing a differentiated platform approach. However, the company is early-stage with quarterly losses and requires validation of its drug candidates in the clinic.
Top Insights
Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash now sufficient to fund operations into the first half of 2028
Collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices for joint R&D activities
Preclinical programs include ABS-101 for inflammatory bowel disease, ABS-201 for androgenic alopecia, ABS-301 for immuno-oncology, and ABS-501 for oncology
Annual revenue reached $35M as of August 2025
Named Competitors
Drug Discovery Platform — Established pharma with AI drug discovery capabilities
mRNA Technology Platform — Platform-based biotech with AI-enabled design
Cell Engineering — Cell therapy and protein design competitor
Recent Developments
(February 2026) Announced Q4 2025 and full year 2025 financial results scheduled for March 24, 2026
(August 2025) Expanded AI Drug Discovery collaboration with Almirall, a dermatology-focused pharma company, selecting second target
(July 2025) Completed $64 million capital raise to extend cash runway to first half of 2028
Open the full interactive Absci Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.